science
Senate Report Finds Most Drugmakers Raised Prices Despite Trump-Era Deals
A recent Senate report indicates that 15 of 16 drugmakers involved in a Trump administration initiative have increased prescription drug prices since early 2025. The report also questions the effectiveness of the TrumpRx online platform in providing savings to patients.
Substrate placeholder — needs reviewAudio version
Tap play to generate a narrated version.
A Senate report released on Thursday found that 15 of the 16 drugmakers participating in a Trump administration initiative have raised the prices of their prescription drugs since January 21, 2025. The report, which cites data from price tracking software NAVLIN, shows that all 16 companies increased prices on 337 drugs during this period.
The drugs affected include treatments for cancer, multiple sclerosis, and cell and gene therapies, with some annual costs rising by more than $14,000 while negotiations with the administration were ongoing.
The report also evaluated the TrumpRx online prescription drug platform, noting that it does not appear to offer significant savings to patients. It highlighted that some drugs available on TrumpRx have lower-cost generic alternatives that are not listed on the site. The report stated that the platform may direct patients toward more expensive drugs rather than the lowest-cost options.
A White House spokesperson responded by stating that the report focuses on list prices, which do not reflect the actual prices paid by patients at pharmacies. U.S.
gov, separate from the list prices that insurance companies pay. The report also noted that since the Trump administration began, these drugmakers have launched 23 new drugs with an average launch price of $353,000.
Additionally, the combined annual profits of these companies increased from $107 billion in 2024 to $177 billion in 2025, a 66 percent rise. The report suggests that Congress could address rising drug prices through legislation requiring drug companies to lower prices to the average level of five peer countries: Canada, France, Germany, Japan, and the United Kingdom.
If companies do not comply, the government would be required to approve low-cost generic alternatives to brand-name drugs.
U.S. adults have used over-the-counter drugs instead of prescriptions due to cost, and about one in five have cut pills in half or skipped doses to save money. The report was released ahead of a Senate Health, Education, Labor and Pensions Committee hearing focused on drug prices.
